A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Endometrial Adenocarcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4
6 insiders sold shares within a month
Since Aug 18, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 350 (planned)
- Started
- Aug 29, 2022
- Main results expected
- May 30, 2027
- Fully finished
- Nov 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.
Measured over: Response will be assessed every 8 weeks from baseline through 2 years or death.
Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative.
Measured over: Response will be assessed every 8 weeks from baseline through 2 years or death.
Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).
Measured over: Response will be assessed every 8 weeks from baseline through 2 years or death.
Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).
Measured over: Response will be assessed every 8 weeks from baseline through 2 years or death.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4, since 2026-08-18, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05548296 · record last updated 2026-08-21 · checked 2026-11-09 15:47 UTC